Indivior completed the acquisition of Opiant Pharmaceuticals for $145m.

Indivior, a global pharmaceutical company, completed the acquisition of Opiant Pharmaceuticals, a biopharmaceutical company developing treatments for addiction and drug overdose, for $145m. "We are pleased to close our combination with Opiant, which provides us with a comprehensive and relevant treatment platform to address the ongoing U.S. opioid and overdose epidemic. We look forward to bringing on Opiant's talented team and undertaking our shared mission to change patients' lives through access to life-transforming treatment for substance use disorders," Mark Crossley, Indivior CEO.